BioSpace News Archive

Gilead Sciences. Inc. (Nasdaq: GILD) is aware of positive data emerging from the National Institute of Allergy and Infectious Diseases’ (NIAID) study of the investigational antiviral remdesivir for the treatment of COVID-19. We understand that the trial has met its primary endpoint and that NIAID will provide detailed information at an upcoming briefing. Remdesivir is not yet licensed or approved anywhere globa

Study Demonstrates Similar Efficacy with 5- and 10-Day Dosing Durations of Remdesivir --

Quantzig, global data analytics and advisory firm, that delivers actionable analytics solutions presents a new case study series that focuses on how coronavirus is impacting businesses across geographies

ProteoGenix, a global leader in antibody production, is pleased to announce the first Human Immune COVID-19 library for the fast discovery of potent antibodies against SARS-CoV-2.

Cantex Pharmaceuticals, Inc., a clinical stage biopharmaceutical company developing proprietary pharmaceuticals for the treatment of cancer and other life-threatening diseases, today announced that Chimerix, Inc., to whom it licensed worldwide rights for the development and commercialization of its lead product, CX-01 (now known as DS

- New animated video, “Together, We Can Solve the Parkinson’s Puzzle,” aims to encourage Parkinson’s patients and families to take part in research to help speed a cure - Narrated by Emmy- and Golden Globe-winning actor Alan Alda, the video can be watched at michaeljfox.org/your-role-research - Content made possible by ACADIA Pharmaceuticals, with additional funding from members of MJFF’s Parkinson’s Disease Education Consortium

Titan Medical Inc. announces that it has closed a US$1.5 million senior secured loan facility (“Loan Facility”) from a leading global medical technology company. The Loan Facility has an interest rate of 8% per annum

Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced the initiation of IND-enabling activities for EDIT-201, an allogeneic natural killer (NK) cell medicine for the treatment of solid tumor cancers. “We have made significant progress in our HDNK (healthy-donor NK) cell medicine program, and we are excited to advance EDIT-201 into development for the treatment of solid tumors,” said Charles Albright, Ph.D

An oral dietary supplement designed to help skin fight photoaging from the inside out.

Mitsubishi Tanabe Pharma Canada, Inc. (MTP-CA), a subsidiary of Mitsubishi Tanabe Pharma America, Inc. (MTPA), today announced that RADICAVA ® (edaravone) is now listed on the Régie de l’assurance maladie du Québec (RAMQ) formulary (special authorization). RADICAVA is an intravenous infusion treatment for amyotrophic lateral sclerosis (ALS), a ra